157 related articles for article (PubMed ID: 32892413)
1. Plasma homocysteine levels are positively associated with interstitial lung disease in dermatomyositis patients with anti-aminoacyl-tRNA synthetase antibody.
Sekiguchi A; Endo Y; Yamazaki S; Uchiyama A; Shimizu A; Motegi SI
J Dermatol; 2021 Jan; 48(1):34-41. PubMed ID: 32892413
[TBL] [Abstract][Full Text] [Related]
2. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
Matsushita T; Hasegawa M; Fujimoto M; Hamaguchi Y; Komura K; Hirano T; Horikawa M; Kondo M; Orito H; Kaji K; Saito Y; Matsushita Y; Kawara S; Yasui M; Seishima M; Ozaki S; Kuwana M; Ogawa F; Sato S; Takehara K
J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
7. The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.
Wakura R; Matsuda S; Kotani T; Shoda T; Takeuchi T
Sci Rep; 2020 Sep; 10(1):15692. PubMed ID: 32973255
[TBL] [Abstract][Full Text] [Related]
8. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
9. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
[TBL] [Abstract][Full Text] [Related]
10. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
[TBL] [Abstract][Full Text] [Related]
12. The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients.
Chen X; Zhang L; Jin Q; Lu X; Lei J; Peng Q; Wang G; Ge Y
Front Immunol; 2022; 13():987841. PubMed ID: 36110863
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
[TBL] [Abstract][Full Text] [Related]
14. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients.
Ikeda N; Takahashi K; Yamaguchi Y; Inasaka M; Kuwana M; Ikezawa Z
J Dermatol; 2011 Oct; 38(10):973-9. PubMed ID: 21883412
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
Lega JC; Cottin V; Fabien N; Thivolet-BĂ©jui F; Cordier JF
J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T
PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468
[TBL] [Abstract][Full Text] [Related]
17. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
18. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.
Hamaguchi Y; Fujimoto M; Matsushita T; Kaji K; Komura K; Hasegawa M; Kodera M; Muroi E; Fujikawa K; Seishima M; Yamada H; Yamada R; Sato S; Takehara K; Kuwana M
PLoS One; 2013; 8(4):e60442. PubMed ID: 23573256
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
Hozumi H; Fujisawa T; Nakashima R; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]